Skip to main content
Top
Published in: Medical Oncology 2/2017

01-02-2017 | Original Paper

Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients

Authors: Pierfrancesco Franco, Monica Rampino, Oliviero Ostellino, Marina Schena, Giancarlo Pecorari, Paolo Garzino Demo, Massimo Fasolis, Francesca Arcadipane, Stefania Martini, Chiara Cavallin, Mario Airoldi, Umberto Ricardi

Published in: Medical Oncology | Issue 2/2017

Login to get access

Abstract

Acute skin toxicity is a frequent finding during combined radiotherapy and chemotherapy in head and neck cancer patients. Its timely and appropriate management is crucial for both oncological results and patient’s global quality of life. We herein report clinical data on the use of Hypericum perforatum and neem oil in the treatment of acute skin toxicity during concurrent chemo-radiation for head and neck cancer. A consecutive series of 50 head and neck cancer patients undergoing concomitant radio-chemotherapy with weekly cisplatin was analyzed. Treatment with Hypericum perforatum and neem oil was started in case of G2 acute skin toxicity according to the RTOG/EORTC scoring scale and continued during the whole treatment course and thereafter until complete recovery. The maximum detected acute skin toxicity included Grade 2 events in 62% of cases and G3 in 32% during treatment and G2 and G3 scores in 52 and 8%, respectively, at the end of chemo-radiation. Grade 2 toxicity was mainly observed during weeks 4–5, while G3 during weeks 5–6. Median times spent with G2 or G3 toxicity were 23.5 and 14 days. Patients with G3 toxicity were reconverted to a G2 profile in 80% of cases, while those with a G2 score had a decrease to G1 in 58% of cases. Time between maximum acute skin toxicity and complete skin recovery was 30 days. Mean worst pain score evaluated with the Numerical Rating Scale-11 was 6.9 during treatment and 4.5 at the end of chemo-radiotherapy. Hypericum perforatum and neem oil proved to be a safe and effective option in the management of acute skin toxicity in head and neck cancer patients submitted to chemo-radiation with weekly cisplatin. Further studies with a control group and patient-reported outcomes are needed to confirm this hypothesis.
Literature
1.
go back to reference Alterio D, Franco P, Numico G, Licitra L, Cossu Rocca M, Ferrari A, et al. Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. Med Oncol. 2016;33:76.CrossRefPubMed Alterio D, Franco P, Numico G, Licitra L, Cossu Rocca M, Ferrari A, et al. Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. Med Oncol. 2016;33:76.CrossRefPubMed
2.
go back to reference Franco P, Fiorentino A, Dionisi F, Fiore M, Chiesa S, Vagge S, et al. Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting. Tumori. 2016;102:459–71.CrossRefPubMed Franco P, Fiorentino A, Dionisi F, Fiore M, Chiesa S, Vagge S, et al. Combined modality therapy for thoracic and head and neck cancers: a review of updated literature based on a consensus meeting. Tumori. 2016;102:459–71.CrossRefPubMed
3.
go back to reference Numico G, Franco P, Cristofano A, Migliaccio F, Spinazzé S, Silvestris N, et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol. 2013;85:112–20.CrossRefPubMed Numico G, Franco P, Cristofano A, Migliaccio F, Spinazzé S, Silvestris N, et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol. 2013;85:112–20.CrossRefPubMed
4.
go back to reference Rampino M, Ricardi U, Munoz F, Reali A, Barone C, Musu AR, et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol. 2011;23:134–40.CrossRef Rampino M, Ricardi U, Munoz F, Reali A, Barone C, Musu AR, et al. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin Oncol. 2011;23:134–40.CrossRef
5.
go back to reference Pignon JP, Le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.CrossRefPubMed Pignon JP, Le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.CrossRefPubMed
6.
go back to reference Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment. J Am Acad Dermatol. 2006;54:28–46.CrossRefPubMed Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment. J Am Acad Dermatol. 2006;54:28–46.CrossRefPubMed
7.
go back to reference Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol. 2015;96:167–82.CrossRefPubMed Russi EG, Moretto F, Rampino M, Benasso M, Bacigalupo A, De Sanctis V, et al. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus. Crit Rev Oncol Hematol. 2015;96:167–82.CrossRefPubMed
8.
go back to reference Iabichella ML. The use of an extract of Hypericum perforatum and Azadirachta indica in advanced diabetic foot: an unexpected outcome. BMJ Case Rep. 2013; pii:bcr2012007299. Iabichella ML. The use of an extract of Hypericum perforatum and Azadirachta indica in advanced diabetic foot: an unexpected outcome. BMJ Case Rep. 2013; pii:bcr2012007299.
9.
go back to reference Wolfle U, Seelinger G, Schempp CM. Topical application of St. John’s Worth (Hypericum Perforatum). Planta Med. 2014;80:109–20.CrossRefPubMed Wolfle U, Seelinger G, Schempp CM. Topical application of St. John’s Worth (Hypericum Perforatum). Planta Med. 2014;80:109–20.CrossRefPubMed
10.
go back to reference Patel SM, Venkata KCN, Bhattacharyya P, Sethi G, Bishavee A. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Semin Cancer Biol. 2016;40–41:100–15.CrossRefPubMed Patel SM, Venkata KCN, Bhattacharyya P, Sethi G, Bishavee A. Potential of neem (Azadirachta indica L.) for prevention and treatment of oncologic diseases. Semin Cancer Biol. 2016;40–41:100–15.CrossRefPubMed
11.
go back to reference Franco P, Potenza I, Moretto F, Segantin M, Grosso M, Lombardo A, et al. Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation of chemo-radiation: a single-arm prospective observational study. Radiat Oncol. 2014;9:297.CrossRefPubMedPubMedCentral Franco P, Potenza I, Moretto F, Segantin M, Grosso M, Lombardo A, et al. Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation of chemo-radiation: a single-arm prospective observational study. Radiat Oncol. 2014;9:297.CrossRefPubMedPubMedCentral
12.
go back to reference Cante D, La Porta MR, Franco P, Sciacero P, Girelli GF, Marra A, et al. Management of ‘in-field’ skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology. 2013;85:257–61.CrossRefPubMed Cante D, La Porta MR, Franco P, Sciacero P, Girelli GF, Marra A, et al. Management of ‘in-field’ skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology. 2013;85:257–61.CrossRefPubMed
13.
go back to reference Franco P, Potenza I, Schena M, Riva G, Pecorari G, Garzino Demo P, et al. Induction chemotherapy and sequential concomitant chemo-radiation in locally advanced head and neck cancers: how induction-phase intensity and treatment breaks may impact on clinical outcomes. Anticancer Res. 2015;35:6247–54.PubMed Franco P, Potenza I, Schena M, Riva G, Pecorari G, Garzino Demo P, et al. Induction chemotherapy and sequential concomitant chemo-radiation in locally advanced head and neck cancers: how induction-phase intensity and treatment breaks may impact on clinical outcomes. Anticancer Res. 2015;35:6247–54.PubMed
14.
go back to reference Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefPubMed
15.
go back to reference Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22–8.CrossRefPubMed Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22–8.CrossRefPubMed
16.
go back to reference Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care (Engl). 2002;11:33–43. Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care (Engl). 2002;11:33–43.
17.
go back to reference Borca VC, Franco P, Catuzzo P, Migliaccio F, Zenone F, Aimonetto S, et al. Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiat Oncol. 2012;7:211.CrossRefPubMedPubMedCentral Borca VC, Franco P, Catuzzo P, Migliaccio F, Zenone F, Aimonetto S, et al. Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiat Oncol. 2012;7:211.CrossRefPubMedPubMedCentral
18.
go back to reference Merlotti A, Alterio D, Vigna-Taglianti R, Muraglia A, Lastrucci L, Manzo R, et al. Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology: head and neck working group. Radiat Oncol. 2014;9:264.CrossRefPubMedPubMedCentral Merlotti A, Alterio D, Vigna-Taglianti R, Muraglia A, Lastrucci L, Manzo R, et al. Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology: head and neck working group. Radiat Oncol. 2014;9:264.CrossRefPubMedPubMedCentral
19.
go back to reference Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92:87–91.PubMed Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92:87–91.PubMed
20.
go back to reference McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006;22:163–73.CrossRefPubMed McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006;22:163–73.CrossRefPubMed
21.
go back to reference Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology. 2001;153:402–14.CrossRefPubMed Greeson JM, Sanford B, Monti DA. St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology. 2001;153:402–14.CrossRefPubMed
22.
go back to reference Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John’s wort that acts by induction of apoptosis. Oncogene. 2002;21:1242–50.CrossRefPubMed Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC, et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John’s wort that acts by induction of apoptosis. Oncogene. 2002;21:1242–50.CrossRefPubMed
23.
go back to reference Dona M, Dell’ Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 2004;64:6225–32.CrossRefPubMed Dona M, Dell’ Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 2004;64:6225–32.CrossRefPubMed
24.
go back to reference Barnes J, Anderson LA, Phillipson JD. St. John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2001;53:583–600.CrossRefPubMed Barnes J, Anderson LA, Phillipson JD. St. John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2001;53:583–600.CrossRefPubMed
25.
go back to reference Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of Hypericum perforatum L. J Ethnopharmacol. 2010;131:511–21.CrossRefPubMed Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of Hypericum perforatum L. J Ethnopharmacol. 2010;131:511–21.CrossRefPubMed
Metadata
Title
Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients
Authors
Pierfrancesco Franco
Monica Rampino
Oliviero Ostellino
Marina Schena
Giancarlo Pecorari
Paolo Garzino Demo
Massimo Fasolis
Francesca Arcadipane
Stefania Martini
Chiara Cavallin
Mario Airoldi
Umberto Ricardi
Publication date
01-02-2017
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0886-5

Other articles of this Issue 2/2017

Medical Oncology 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.